RDY's Q4 Results in Detail Dr. Reddy's reported revenues under three segments — Global Generics, Pharmaceutical Services & Active Ingredients (PSAI) and Others. Global Generics revenues totaled INR 65.8 billion, down 13% year over year. The decrease was mainly due to lower North America generics sales, partly offset by broad-based growth across key markets supported by favorable foreign exchange movements. Key Takeaways Dr. Reddy's Laboratories Limited (RDY) reported fourth-quarter fiscal 2026 adjusted earn ...

Dr. Reddy's Laboratories (NYSE:RDY) Q4 2026 Earnings call May 12, 2026 10:00 AM ET Company Participants Aishwarya Tripathy - Talent Advisor Ashutosh Jha - Software Developer Erez Israeli - CEO M.V. Narasimham - CFO M.V. Ramana - CEO, Branded Markets Conference Call Participants Alok Dalal - Analyst Bino Pathiparampil - Analyst Damayanti Kerai - Analyst Lavanya Tottala - Analyst Neha Manpuria - Analyst Saion Mukherjee - Analyst Sidharth Nigandhi - Analyst Surya Patra - Analyst Tushar Manudhane - Analyst Vish ...

Alok Dalal - Analyst Ashutosh Jha - Analyst Bino Pathiparampil - Analyst Damayanti Kerai - Analyst Lavanya Tottala - Analyst Neha Manpuria - Analyst Saion Mukherjee - Analyst Siddharth Nigande - Analyst Surya Patra - Analyst Tushar Manudhane - Analyst Vishal Manchanda - Analyst Vivek Agarwal - Analyst Aishwarya Tripathy Our Chief Executive Officer, and Mr. M.V. Narasimhan, our Chief Financial Officer. Our quarterly financial results have been published earlier today and are available on our website for your ...

Dr. Reddy's Laboratories (NYSE:RDY) Q4 2026 Earnings call May 12, 2026 10:00 AM ET Speaker0 Our Chief Executive Officer, and Mr. M.V. Narasimhan, our Chief Financial Officer. Our quarterly financial results have been published earlier today and are available on our website for your reference. We will start today's call with M.V.N. providing an overview of our financial performance for the quarter as well as the year. Following that, Hari will share his insights on key business highlights as well as the comp ...

Q4 & FY26 RESULTS UPDATE Dr. Reddy's 12 MAY 2026 1 | September 2025 | Investor Presentation | As per consolidated financial statements under IFRS Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact ...

Indian drugmaker Dr Reddy's reported an 86% slump in quarterly profit on Tuesday, hurt by pricing pressure and increasing competition in its key U.S. market. ...

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the best cancer stocks on our list. TheFly reported on April 23 that Goldman Sachs lowered its rating on RDY from Neutral to Sell and reduced the price target from INR 1,225 to INR 1,075, citing concerns that the company’s generic Ozempic prospects in Canada may be weaker and more short-term than previously expected due to rising competition. The firm also noted that RDY ...